However, the NF2 gene fusion-based biomarker for the prediction of meningioma progression or recurrence might not be reliable in clinical practice as radiation therapy could induce new NF2 mutations or structural variants in meningioma [10,20]. This evidence concerns the gene NF2 and meningioma.